NEC Corporation has developed an AI technology for supporting doctors in determining if colorectal lesions are neoplastic or non-neoplastic.
NEC, National Cancer Center Japan
NEC developed a new technology, called “Cx20," while seeking to assist in the early detection of colorectal lesions. Cx20 has already met the requirements for CE marking and will be integrated in the medical device AI diagnostic support software "WISE VISION Endoscopy" with sales expected to start in Europe later this year.
This software connects and interacts with existing endoscopic equipment and automatically notifies users if a lesion is possibly neoplastic based on images captured during endoscopy procedures. The software then becomes an extra tool immediately available to assist endoscopists in the differentiation of lesions and reduces the burden on patients.
Colorectal cancer originates from precancerous lesions (colorectal neoplastic polyps) and it is possible to suppress its progression by detecting and removing lesions at an early stage during endoscopy procedures. It is, however, sometimes difficult for endoscopists to visually distinguish between neoplastic and non-neoplastic lesions during endoscopy examinations, resulting in unnecessary biopsies and removal of non-neoplastic lesions, thereby causing additional stress and discomfort to patients. Colorectal cancer is said to be the second-largest cancer in the European region, and the latest version of WISE VISION Endoscopy, which launches first in Europe, promises to help doctors address this challenging issue.
To improve the chances of identifying if colorectal lesions are possibly neoplastic, and so to help endoscopists in their decision process, NEC developed a new technology where the learning power of AI is used to combine information of endoscopy images and data from the findings of expert physicians. Specifically, the technology analyses still images of lesions taken with endoscopy devices, and if the AI determines that a colorectal lesion is likely to be neoplastic a "high possibility" notification message is displayed.
NEC and the National Cancer Centre Japan have been collaborating since 2016 to develop a technology that automatically detects suspected colorectal lesions during endoscopy examinations. NEC began sales of software incorporating this technology in January of this year. With the addition of this function in Europe, WISE VISION Endoscopy aims to help reduce the burden on doctors and patients by providing additional and immediately beneficial support during the examination process. In developing this solution NEC applied its face recognition technology, belonging to its portfolio of AI based technologies which has been evaluated by the National Institute of Standards and Technology (NIST) in the United States. In the future, NEC will further promote joint research with the National Cancer Centre Japan to further enhance the performance of its AI technology and to assist endoscopists with its usage.
